BRPI0506740A - complexos de metal possuindo vitamina b12, como um ligante - Google Patents

complexos de metal possuindo vitamina b12, como um ligante

Info

Publication number
BRPI0506740A
BRPI0506740A BRPI0506740-5A BRPI0506740A BRPI0506740A BR PI0506740 A BRPI0506740 A BR PI0506740A BR PI0506740 A BRPI0506740 A BR PI0506740A BR PI0506740 A BRPI0506740 A BR PI0506740A
Authority
BR
Brazil
Prior art keywords
vitamin
metal complexes
binder
cyanide
complex
Prior art date
Application number
BRPI0506740-5A
Other languages
English (en)
Inventor
Roger Alberto
Hector Humberto Knight Castro
Stefan Mundweiler
Susanne Barbara Kunze
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of BRPI0506740A publication Critical patent/BRPI0506740A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPLEXOS DE METAL POSSUINDO VITAMINA B~ 12~ COMO UM LIGANTE. A presente invenção refere-se ao complexo de metal da fórmula geral <sym), onde cada L é indenpendentemente selecionado e representa um ligante e pelo menos um L é vitamina B~ 12~ (cianocobalamina) ou um derivado da mesma ligado através do átomo de nitrogênio do seu grupo cianeto a M, que é um elemento selecionado de metais de transição, assim formando uma fração M-NC-¢Co!, com ¢Co! representado a vitamina B~ 12~ sem cianeto e onde n é 1, 2, 3, 4, 5 ou 6. O complexo pode ser preparado por mistura de uma molécula precursora com vitamina B~ 12~ Os complexos de metal podem ser usados para radiodiagnósticos, quimioterapia e radionuclídeo terapia.
BRPI0506740-5A 2004-01-08 2005-01-10 complexos de metal possuindo vitamina b12, como um ligante BRPI0506740A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04075003 2004-01-08
EP04077937 2004-10-25
PCT/EP2005/000168 WO2005068483A1 (en) 2004-01-08 2005-01-10 Metal complexes having vitamin b12 as a ligand

Publications (1)

Publication Number Publication Date
BRPI0506740A true BRPI0506740A (pt) 2007-05-15

Family

ID=34796701

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506740-5A BRPI0506740A (pt) 2004-01-08 2005-01-10 complexos de metal possuindo vitamina b12, como um ligante

Country Status (12)

Country Link
US (1) US7692002B2 (pt)
EP (1) EP1704157B1 (pt)
JP (1) JP2007518727A (pt)
KR (1) KR20070010119A (pt)
AT (1) ATE443070T1 (pt)
AU (1) AU2005205126A1 (pt)
BR (1) BRPI0506740A (pt)
CA (1) CA2552916C (pt)
DE (1) DE602005016648D1 (pt)
ES (1) ES2334923T3 (pt)
IL (1) IL176664A (pt)
WO (1) WO2005068483A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101019555B (zh) * 2007-03-23 2011-03-30 南京师范大学 稀土-氨基酸-维生素三元配合物植物生长调节剂及其制备方法
CN102791724A (zh) * 2010-03-08 2012-11-21 苏黎世大学 用于医疗用途的一氧化碳释放铼化合物
WO2012061477A1 (en) 2010-11-02 2012-05-10 Promega Corporation Coelenterazine derivatives and methods of using same
US8669103B2 (en) 2010-11-02 2014-03-11 Promega Corporation Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
US9385033B2 (en) * 2013-09-27 2016-07-05 Intel Corporation Method of forming a metal from a cobalt metal precursor
JP6588917B2 (ja) 2014-01-29 2019-10-09 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ 生細胞への適用のためのプロ基質
US9790537B2 (en) 2014-01-29 2017-10-17 Promega Corporation Quinone-masked probes as labeling reagents for cell uptake measurements

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560782A (en) * 1982-11-19 1985-12-24 Research Corporation Anti-tumor diplatinum coordination compounds
US4673631A (en) * 1984-12-15 1987-06-16 Canon Kabushiki Kaisha Toner, charge-imparting material and composition containing metal complex
JPH03504450A (ja) * 1988-05-09 1991-10-03 ザ・パブリツク・ヘルス・ラボラタリイ・サーヴイス・ボード 脱ハロゲン化における金属キレート錯体の使用
US5393909A (en) * 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
GB8910760D0 (en) * 1989-05-10 1989-06-28 Health Lab Service Board Corrin mediated degradation of organic nitrogen compounds
DE19712388A1 (de) * 1997-03-25 1998-10-01 Studiengesellschaft Kohle Mbh Verfahren zur Synthese von aromatisch substituierten Olefinen
US6844425B1 (en) * 1999-02-24 2005-01-18 Mallinckrodt Inc. Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
US6797521B2 (en) * 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
US6180087B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Tunable indocyanine dyes for biomedical applications
US6180085B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Dyes
ES2476899T3 (es) * 2001-01-30 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd. Medicamentos contra el cáncer de pulmón
DE60326465D1 (de) * 2002-09-03 2009-04-16 Univ Zuerich Herstellung von m(co)3-komplexen durch festphasentechniken durch metal-unterstützte trennung vom festen träger

Also Published As

Publication number Publication date
IL176664A0 (en) 2006-10-31
KR20070010119A (ko) 2007-01-22
AU2005205126A1 (en) 2005-07-28
EP1704157A1 (en) 2006-09-27
ES2334923T3 (es) 2010-03-17
CA2552916A1 (en) 2005-07-28
JP2007518727A (ja) 2007-07-12
CA2552916C (en) 2014-11-18
EP1704157B1 (en) 2009-09-16
ATE443070T1 (de) 2009-10-15
IL176664A (en) 2013-05-30
WO2005068483A1 (en) 2005-07-28
US7692002B2 (en) 2010-04-06
DE602005016648D1 (de) 2009-10-29
US20090175775A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
BRPI0506740A (pt) complexos de metal possuindo vitamina b12, como um ligante
TW200633976A (en) Organic silver complexes, their preparation methods and their methods for forming thin layers
ATE503746T1 (de) Neue imidazolidinderivate
TW200720399A (en) Light-emitting element and iridium complex
ATE542792T1 (de) Quellen asymmetrischer ligangen, metallhaltige verbindungen mit reduzierter symmetrie und system und verfahren, bei denen diese eingesetzt werden
MY184464A (en) Combined use of cholestanol derivative
DK1561754T3 (da) Fremgangsmåde til fremstilling af 1,2-diaminocyclohexanplatin(II)-komplekser
TW200732337A (en) Organic compounds
WO2007011417A3 (en) Metallic chromonic compounds
WO2008064959A3 (de) Metallverbindungen als initiatoren
MXPA04000210A (es) Conjugados quelantes mejorados.
DK1079832T3 (da) Anvendelse af vitamin-PP-forbindelser
TW200724547A (en) Bidentate C, P chiral phosphine ligands
BRPI0410635A (pt) isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste
TW200740835A (en) Transition metal complexes and preparation methods thereof
ATE471331T1 (de) Neue übergangsmetall-komplexe und deren einsatz in übergangsmetall-katalysierten reaktionen
WO2009010129A8 (de) Bispidonliganden und deren metallkomplexe
WO2009007676A3 (en) Biomolecule binding ligands
EA200800326A1 (ru) Способ получения 3-оксо-прегн-4-ен-21,17-карболактонов с помощью окисления 17-(3-гидроксипропил)-3,17-дигидроксиандростанов без использования металла
ATE530557T1 (de) Diphosphinliganden
IL193064A0 (en) Metal complexes
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
ZA200801517B (en) Chemical process
ATE471513T1 (de) Neue chemilumineszenzverbindungen und ihre verwendung
ATE482220T1 (de) Organische molybdänverbindungen und diese verbindungen enthaltende schmierzusammensetzungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.